​On April 2, 2020, Savara Inc., an orphan lung disease company, announced the company has entered into an exclusive license and collaboration agreement with Grifols for Apulmiq (inhaled liposomal ciprofloxacin) after Grifols had acquired the assets in a bankruptcy process. Wilson Sonsini Goodrich & Rosati represented Savara in the transaction.

Apulmiq, also known as Linhaliq in Europe, is a late-stage investigational inhaled antibiotic in Phase 3 development for the treatment of non-cystic fibrosis bronchiectasis. Under the terms of the agreement, Savara has obtained the worldwide rights to develop and commercialize Apulmiq. Savara provided an upfront payment and, if regulatory approval is obtained, Grifols will be eligible for regulatory milestone payments as well as royalties and potential tiered sales milestones upon commercialization.

The Wilson Sonsini team representing Savara in the transaction includes Robert Suffoletta, Ben Hoch, Marsha Sukach, and John Wehrli​.

For more information, please see Savara's press release.